0
Correspondence |

ResponseResponse FREE TO VIEW

Gustavo J. Rodrigo, MD; José A. Castro-Rodríguez, MD, PhD
Author and Funding Information

From the Departamento de Emergencia (Dr Rodrigo), Hospital Central de las Fuerzas Armadas; and Departments of Pediatrics and Family Medicine (Dr Castro-Rodríguez), School of Medicine, Pontificia Universidad Católica de Chile.

CORRESPONDENCE TO: Gustavo J. Rodrigo, MD, Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Av 8 de Octubre 3020, Montevideo 11600, Uruguay; e-mail: gustavo.javier.rodrigo@gmail.com


FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following conflicts: Dr Rodrigo has participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Air Products & Chemicals, Inc; Almiral, SA; AstraZeneca; Boehringer Ingelheim GmbH; Esteve; GlaxoSmithKline plc; Merck Sharp & Dohme Corp; and Novartis AG. Dr Castro-Rodríguez has participated as a lecturer and speaker in scientific meetings and courses under the sponsorship of Merck Sharp & Dohme Corp, GlaxoSmithKline plc, and Grünenthal and as member of the advisory board for GlaxoSmithKline plc.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2015;147(5):e196. doi:10.1378/chest.15-0194
Text Size: A A A
Published online
To the Editor:

We appreciate the interest of Dr Dahl in our recent article in CHEST1 on the role of tiotropium for patients with asthma. Dr Dahl is concerned with the potential undesirable effects related to the use of tiotropium. In this sense, he is correct in asserting that the warnings come only from the use of tiotropium in patients with COPD. On the contrary, tiotropium appears to be safe and well tolerated in patients with asthma (one of the conclusions of our article). Therefore, it is questionable whether the Tiotropium Safety and Performance in Respimat (TIOSPIR) trial2 should be referenced in our article, because it was not conducted on patients with asthma. In any case, the results of our article regarding the safety of tiotropium in asthma were similar to those of the TIOSPIR study for COPD.

References

Rodrigo GJ, Castro-Rodríguez JA. What is the role of tiotropium in asthma? A systematic review with meta-analysis. Chest. 2015;147(2):388-396. [CrossRef] [PubMed]
 
Wise RA, Anzueto A, Cotton D, et al; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491-1501. [CrossRef] [PubMed]
 

Figures

Tables

References

Rodrigo GJ, Castro-Rodríguez JA. What is the role of tiotropium in asthma? A systematic review with meta-analysis. Chest. 2015;147(2):388-396. [CrossRef] [PubMed]
 
Wise RA, Anzueto A, Cotton D, et al; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491-1501. [CrossRef] [PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543